MedTrace Logo

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

NCT06932562 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-03-25

No results posted yet for this study

Summary

This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible).

The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.

Conditions

Interventions

DRUG

Linvoseltamab

Administered per the protocol

DRUG

Daratumumab

Administered per the protocol

DRUG

Lenalidomide

Administered per the protocol

DRUG

Dexamethasone

Administered per the protocol

Sponsors & Collaborators

Principal Investigators

  • Roberto Mina · A.O.U. Città della Salute e della Scienza di Torino

  • Claudia Stege · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-23
Primary Completion
2036-12-31
Completion
2036-12-31
FDA Drug
Yes

Countries

  • Australia
  • Austria
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • Switzerland
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932562 on ClinicalTrials.gov